PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a ...

PureTech also has discovery and preclinical-stage candidates in oncology, including anti-Galectin-9 and Delta-1 antibodies for solid tumours. Image by Gerd Altmann from Pixabay Image ...

UBS Global Healthcare Conference Presenters: Bharatt Chowrira, Ph.D., J.D., Chief Executive Officer, and Eric Elenko, Ph.D., Co-founder and President Date: Wednesday, November 13, 2024 Time: 8:45 a.m.

Highlights,Seaport Therapeutics has successfully closed a $225 million Series B financing round, increasing total capital ...

PureTech also argues the device has a favourable safety profile, as its active ingredients do not enter the bloodstream, thereby giving it a safety profile similar to placebo.

PureTech Health (GB:PRTC) has released an update. PureTech Health, a clinical-stage biotherapeutics company, announced a transfer of shares by non-executive director John LaMattina to support ...

Boston-based Seaport Therapeutics closed $225 million in new capital, bringing its total funding to $325 million.

PureTech Systems Inc., a pioneer in geospatial AI-boosted video analytics for wide-area perimeter and border security, announced the release of its new Interface Control Document (ICD). This essential ...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with ...